This is a news story, published by Harvard Gazette, that relates primarily to Wegovy news.
For more Wegovy news, you can click here:
more Wegovy newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Harvard Gazette, you can click here:
more news from Harvard GazetteOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
loss drug Wegovy. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest metabolic drug news, Wegovy news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
weekly Wegovy shotsHarvard Gazette
•
87% Informative
The trial was led by Harvard -affiliated Brigham and Women’s Hospital .
The researchers do not know if the benefit of Wegovy is due to weight loss or other effects, but suggest that extra weight may be the greatest contributor to lower life expectancy.
Further studies will explore potential mechanisms of action and other studies of drugs in this class should provide additional data.
VR Score
94
Informative language
99
Neutral language
59
Article tone
formal
Language
English
Language complexity
69
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
long-living
External references
1
Source diversity
1
Affiliate links
no affiliate links